Question 1

What specific type of non-Hodgkin's lymphoma do I have, and does it qualify for this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

Question 2

How does elsamitrucin compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of elsamitrucin?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any other trials or treatments I should consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma clinical trial (NCT00090090). Contact the study team or your healthcare provider for specific answers.

What this study is about